Person:
Stroopinsky, Dina

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Stroopinsky

First Name

Dina

Name

Stroopinsky, Dina
Author's Publications: search.filters.isAuthorOfPublication.d63ae92a-50b8-4f13-8c5a-cde62a283dc6

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    MUC1 Inhibition Leads to Decrease in PD-L1 Levels via Up-Regulation of miRNAs
    (Springer Nature, 2017) Pyzer, Athalia Rachel; Stroopinsky, Dina; Rosenblatt, Jacalyn; Anastasiadou, Eleni; Rajabi, Hasan; Washington, Abigail; Tagde, Ashujit; Chu, Jen-Hwa; Coll, Maxwell; Jiao, AL; Tsai, LT; Tenen, DE; Cole, Leandra Samantha; Palmer, Kristen; Ephraim, A; Leaf, Rebecca Karp; Nahas, Myrna; Apel, Arie; Bar-Natan, M; Jain, Salvia; McMasters, Malgorzata; Mendez, Lourdes; Arnason, Jon; Raby, Benjamin; Slack, Frank; Kufe, Donald; Avigan, David
    The PD-L1/PD-1 pathway is a critical component of the immunosuppressive tumor microenvironment in acute myeloid leukemia (AML), but little is known about its regulation. We investigated the role of the MUC1 oncoprotein in modulating PD-L1 expression in AML. Silencing of MUC1 in AML cell lines suppressed PD-L1 expression without a decrease in PD-L1 mRNA levels, suggesting a post-transcriptional mechanism of regulation. We identified the microRNAs miR-200c and miR-34a as key regulators of PD-L1 expression in AML. Silencing of MUC1 in AML cells led to a marked increase in miR-200c and miR-34a levels, without changes in precursor microRNA, suggesting that MUC1 might regulate microRNA-processing. MUC1 signaling decreased the expression of the microRNA-processing protein DICER, via the suppression of c-Jun activity. NanoString (Seattle, WA, USA) array of MUC1-silenced AML cells demonstrated an increase in the majority of probed microRNAs. In an immunocompetent murine AML model, targeting of MUC1 led to a significant increase in leukemia-specific T cells. In concert, targeting MUC1 signaling in human AML cells resulted in enhanced sensitivity to T-cell-mediated lysis. These findings suggest MUC1 is a critical regulator of PD-L1 expression via its effects on microRNA levels and represents a potential therapeutic target to enhance anti-tumor immunity.
  • Thumbnail Image
    Publication
    MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia
    (Impact Journals LLC, 2016) Tagde, Ashujit; Rajabi, Hasan; Stroopinsky, Dina; Gali, Rayappa; Alam, Maroof; Bouillez, Audrey; Kharbanda, Surender; Stone, Richard; Avigan, David; Kufe, Donald
    Aberrant DNA methylation is a hallmark of acute myeloid leukemia (AML); however, the regulation of DNA methyltransferase 1 (DNMT1), which is responsible for maintenance of DNA methylation patterns, has largely remained elusive. MUC1-C is a transmembrane oncoprotein that is aberrantly expressed in AML stem-like cells. The present studies demonstrate that targeting MUC1-C with silencing or a pharmacologic inhibitor GO-203 suppresses DNMT1 expression. In addition, MUC1 expression positively correlates with that of DNMT1 in primary AML cells, particularly the CD34+/CD38− population. The mechanistic basis for this relationship is supported by the demonstration that MUC1-C activates the NF-κB p65 pathway, promotes occupancy of the MUC1-C/NF-κB complex on the DNMT1 promoter and drives DNMT1 transcription. We also show that targeting MUC1-C substantially reduces gene promoter-specific DNA methylation, and derepresses expression of tumor suppressor genes, including CDH1, PTEN and BRCA1. In support of these results, we demonstrate that combining GO-203 with the DNMT1 inhibitor decitabine is highly effective in reducing DNMT1 levels and decreasing AML cell survival. These findings indicate that (i) MUC1-C is an attractive target for the epigentic reprogramming of AML cells, and (ii) targeting MUC1-C in combination with decitabine is a potentially effective clinical approach for the treatment of AML.